Michael R. Nichols, MA (he/him/his)

Merida Biosciences
Cambridge, NY, United States

Disclosure information not submitted.

Presentation(s):

• MON-364 - NEXUS STUDY: A Phase 1 Trial to Evaluate MER511, A Fusion Protein Designed to Eliminate Circulating Pathogenic Anti-TSHR Autoantibodies for the Treatment of Graves' Disease

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT